Security
ALX Oncology Holdings Inc. Common Stock · ALXO
ALXONASDAQCommon stockCurrentCIK 1810182Updated Oct 19, 2026
ALXO price & chart
Loading TradingView…
NASDAQ:ALXO on TradingView ↗About the company
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X.
In the news
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules ↗
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge News provided by USA News Group Mar 08, 2025, 07:33 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Mar ↗
Seeking Alpha
ALX Oncology GAAP EPS of -$0.13 ↗
ALX Oncology: Rebuilding From Critical Setbacks ↗
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS ↗
SEC disclosures
ALX ONCOLOGY HOLDINGS INC files 8-K: Material Event ↗
Recent filings
SCHEDULE 13D/A - filed by venBio Global Strategic Fund, L.P. regarding ALX ONCOLOGY HOLDINGS INC
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
4 filing
SCHEDULE 13G/A - filed by TCG Crossover GP II, LLC regarding ALX ONCOLOGY HOLDINGS INC
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 5.02, 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 1.02, 2.03, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 82,723,000Source | 185,715,000Source | 160,820,000Source | 95,320,000Source | 214,618,000Source | 178,328,000Source | 120,900,000Source | 212,650,000Source | 59,046,000Source | 147,775,000Source | 242,553,000Source | 306,489,000Source |
| Property, Plant and Equipment, NetUSD | 1,351,000Source | 3,112,000Source | 166,000Source | 1,497,000Source | 3,316,000Source | 1,050,000Source | 2,703,000Source | 3,441,000Source | 1,200,000Source | 2,905,000Source | 3,589,000Source | 3,889,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,442,000Source | 16,102,000Source | 22,687,000Source | 19,302,000Source | 15,534,000Source | 32,284,000Source | 20,614,000Source | 14,041,000Source | 16,373,000Source | 17,567,000Source | 22,406,000Source | 48,822,000Source |
| Assets, CurrentUSD | 66,516,000Source | 155,895,000Source | 143,457,000Source | 85,257,000Source | 168,712,000Source | 145,564,000Source | 102,532,000Source | 167,864,000Source | 50,727,000Source | 134,352,000Source | 188,659,000Source | 270,969,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,890,000Source | 7,321,000Source | 5,228,000Source | 5,943,000Source | 11,989,000Source | 5,240,000Source | 4,701,000Source | 10,427,000Source | 5,937,000Source | 6,595,000Source | 5,923,000Source | 4,762,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,306,000Source | 4,234,000Source | 235,000Source | 1,453,000Source | 4,442,000Source | 1,010,000Source | 3,807,000Source | 4,647,000Source | 1,159,000Source | 4,023,000Source | 4,847,000Source | 5,626,000Source |
| Other Assets, NoncurrentUSD | 9,018,000Source | 12,672,000Source | 2,050,000Source | 4,334,000Source | 13,115,000Source | 2,931,000Source | 6,504,000Source | 14,296,000Source | 3,625,000Source | 6,994,000Source | 14,894,000Source | 14,932,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 37,923,000Source | 48,908,000Source | 24,633,000Source | 30,905,000Source | 55,301,000Source | 26,981,000Source | 32,605,000Source | 48,455,000Source | 33,065,000Source | 34,157,000Source | 52,841,000Source | 43,025,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 54,000Source | 53,000Source | 138,000Source | 54,000Source | 52,000Source | 135,000Source | 53,000Source | 50,000Source | 54,000Source | 53,000Source | 50,000Source | 41,000Source |
| Retained Earnings (Accumulated Deficit)USD | -699,969,000Source | -591,959,000Source | -758,715,000Source | -677,825,000Source | -561,252,000Source | -740,744,000Source | -651,876,000Source | -521,853,000Source | -722,817,000Source | -621,122,000Source | -486,272,000Source | -325,467,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 43,000Source | 563,000Source | -224,000Source | 36,000Source | -73,000Source | -245,000Source | 118,000Source | 28,000Source | 28,000Source | 275,000Source | 256,000Source | -845,000Source |
| Stockholders' Equity Attributable to ParentUSD | 44,800,000Source | 136,807,000Source | 136,187,000Source | 64,415,000Source | 159,317,000Source | 151,347,000Source | 88,295,000Source | 164,195,000Source | 25,981,000Source | 113,618,000Source | 189,712,000Source | 263,464,000Source |
| Additional Paid in Capital, Common StockUSD | 744,672,000Source | 728,150,000Source | 894,988,000Source | 742,150,000Source | 720,590,000Source | 892,201,000Source | 740,000,000Source | 685,970,000Source | 748,716,000Source | 734,412,000Source | 675,678,000Source | 589,735,000Source |
| Liabilities and EquityUSD | 82,723,000Source | 185,715,000Source | 160,820,000Source | 95,320,000Source | 214,618,000Source | 178,328,000Source | 120,900,000Source | 212,650,000Source | 59,046,000Source | 147,775,000Source | 242,553,000Source | 306,489,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 27,722,000Source | 32,340,000Source | 14,776,000Source | 18,848,000Source | 38,449,000Source | 20,178,000Source | 18,742,000Source | 32,228,000Source | 24,553,000Source | 18,500,000Source | 36,001,000Source | 28,325,000Source |
| Operating Lease, Liability, CurrentUSD | 990,000Source | 923,000Source | 244,000Source | 1,003,000Source | 897,000Source | 813,000Source | 976,000Source | 872,000Source | 901,000Source | 949,000Source | 847,000Source | 755,000Source |
| Accounts Payable, CurrentUSD | 6,583,000Source | 7,891,000Source | 3,022,000Source | 4,902,000Source | 8,146,000Source | 3,854,000Source | 3,937,000Source | 6,227,000Source | 4,914,000Source | 4,497,000Source | 8,591,000Source | 8,073,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,718,000Source | 3,708,000Source | 0Source | 2,947,000Source | 3,950,000Source | 2,396,000Source | 3,208,000Source | 4,184,000Source | 2,561,000Source | 3,462,000Source | 4,411,000Source | 5,258,000Source |
| Other Liabilities, NoncurrentUSD | 4,437,000Source | 6,733,000Source | 152,000Source | 5,060,000Source | 7,083,000Source | 3,508,000Source | 5,631,000Source | 6,524,000Source | 3,980,000Source | 6,188,000Source | 7,201,000Source | 5,311,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | 4,348,000Source | 0Source | 0Source | 3,043,000Source | 0Source | 5,217,000Source | 1,739,000Source | 0Source | 5,217,000Source | 435,000Source | 0Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 5,764,000Source | 9,835,000Source | 9,705,000Source | 6,997,000Source | 9,769,000Source | 3,295,000Source | 8,232,000Source | 9,703,000Source | 4,532,000Source | 9,469,000Source | 9,639,000Source | 9,389,000Source |
| Short-term InvestmentsUSD | 37,184,000Source | 132,472,000Source | 115,542,000Source | 60,012,000Source | 141,189,000Source | 108,040,000Source | 77,217,000Source | 143,396,000Source | 28,417,000Source | 110,190,000Source | 160,330,000Source | 217,385,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -17,927,000Source | -30,754,000Source | -101,695,000Source | -134,850,000Source | -160,805,000Source | -123,482,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 150,000Source | 211,000Source | 706,000Source | 872,000Source | 836,000Source | 342,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,509,000Source | 5,216,000Source | 12,579,000Source | 27,093,000Source | 26,273,000Source | 23,839,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,210,000Source | -556,000Source | 421,000Source | -4,024,000Source | 458,000Source | 4,506,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,648,000Source | -24,663,000Source | -84,142,000Source | -121,912,000Source | -130,364,000Source | -89,223,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -105,036,000Source | 27,645,000Source | 82,586,000Source | 86,256,000Source | 44,657,000Source | -235,416,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 50,000Source | 60,000Source | 212,000Source | 447,000Source | 1,274,000Source | 1,427,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 139,595,000Source | 65,000Source | 362,000Source | 30,817,000Source | 59,291,000Source | 9,860,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 23,508,000Source | 16,168,000Source | 22,953,000Source | 19,368,000Source | 32,350,000Source | 20,680,000Source | 16,439,000Source | 17,633,000Source | 22,472,000Source | 48,888,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 1,259,000Source | 1,387,000Source | 1,177,000Source | 103,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,521,000Source | 6,952,000Source | 2,683,000Source | 2,136,000Source | 2,509,000Source | 5,216,000Source | 12,579,000Source | 27,093,000Source | 26,273,000Source | 23,839,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 68,000Source | 67,000Source | 280,000Source | 265,000Source | 250,000Source | 44,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | -200,000Source | — | — | — | — | -10,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,091,000Source | 6,096,000Source | 5,133,000Source | 5,451,000Source | 5,360,000Source | 7,932,000Source | 23,850,000Source | 26,094,000Source | 28,483,000Source | 29,036,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 64,000Source |
| Investment Income, InterestUSD | — | — | 802,000Source | 2,303,000Source | 1,508,000Source | 1,106,000Source | 1,182,000Source | 1,483,000Source | 3,964,000Source | 9,366,000Source | 10,649,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,144,000Source | -30,707,000Source | -17,971,000Source | -25,949,000Source | -17,927,000Source | -30,754,000Source | -101,695,000Source | -134,850,000Source | -160,805,000Source | -123,482,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -123,482,000Source |
| Operating ExpensesUSD | — | — | 22,532,000Source | 32,567,000Source | 18,033,000Source | 26,648,000Source | 18,966,000Source | 31,820,000Source | 104,021,000Source | 142,467,000Source | 170,278,000Source | 127,436,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | 3,000Source | -257,000Source | -2,000Source | 188,000Source | -11,000Source | -36,000Source | -20,000Source | 389,000Source | -260,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 124,486,000Source | 15,775,000Source | 51,593,000Source | 107,406,000Source | 246,629,000Source | 376,789,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 11,000Source | 372,000Source | 1,688,000Source | 29,661,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 670,000Source | — | 14,000Source | 1,632,000Source | 269,000Source | 567,000Source |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating Income (Loss)USD | — | — | -22,532,000Source | -32,567,000Source | -18,033,000Source | -26,648,000Source | -18,966,000Source | -31,820,000Source | -104,021,000Source | -142,467,000Source | -170,278,000Source | -127,436,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | 3,000Source | -257,000Source | -2,000Source | 188,000Source | -11,000Source | -36,000Source | -20,000Source | 389,000Source | -260,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -101,695,000Source | -134,850,000Source | -160,805,000Source | -123,418,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 64,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,144,000Source | -30,707,000Source | -17,971,000Source | -25,949,000Source | -17,927,000Source | -30,754,000Source | -101,695,000Source | -134,850,000Source | -160,805,000Source | -123,482,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.41Source | -0.58Source | -0.13Source | -0.49Source | -0.17Source | -0.58Source | -1.9Source | -2.58Source | -3.74Source | -3.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.41Source | -0.58Source | -0.13Source | -0.49Source | -0.17Source | -0.58Source | -1.9Source | -2.58Source | -3.74Source | -3.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 53,577,066Source | 52,693,878Source | 135,639,684Source | 53,445,631Source | 104,573,657Source | 53,359,338Source | 53,658,399Source | 52,174,904Source | 42,987,767Source | 40,699,612Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 53,577,066Source | 52,693,878Source | 135,639,684Source | 53,445,631Source | 104,573,657Source | 53,359,338Source | 53,658,399Source | 52,174,904Source | 42,987,767Source | 40,699,612Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 64,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 200,000Source | 200,000Source | 100,000Source | 200,000Source | 100,000Source | 200,000Source | 700,000Source | 900,000Source | 800,000Source | 300,000Source |
| General and Administrative ExpenseUSD | — | — | 5,091,000Source | 6,096,000Source | 5,133,000Source | 5,451,000Source | 5,360,000Source | 7,932,000Source | 23,850,000Source | 26,094,000Source | 28,483,000Source | 29,036,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -101,198,000Source | -134,120,000Source | -159,766,000Source | -111,360,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -3.03Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -3.03Source |
| Interest ExpenseUSD | — | — | 408,000Source | 446,000Source | 285,000Source | 405,000Source | 331,000Source | 406,000Source | 1,602,000Source | 1,729,000Source | 1,565,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 4,278,000Source |
| Investment Income, InterestUSD | — | — | 802,000Source | 2,303,000Source | 1,508,000Source | 1,106,000Source | 1,182,000Source | 1,483,000Source | 3,964,000Source | 9,366,000Source | 10,649,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -123,482,000Source |
| Operating ExpensesUSD | — | — | 22,532,000Source | 32,567,000Source | 18,033,000Source | 26,648,000Source | 18,966,000Source | 31,820,000Source | 104,021,000Source | 142,467,000Source | 170,278,000Source | 127,436,000Source |
| Research and Development ExpenseUSD | — | — | 17,441,000Source | 26,471,000Source | 13,138,000Source | 18,022,000Source | 13,606,000Source | 23,888,000Source | 76,996,000Source | 116,373,000Source | 141,795,000Source | 98,400,000Source |
| Other General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
alxo-ex4_1.htm · 8-K · 2026-10-15
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUC…
Read attachment ↗alxo-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer - - Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven d…
Read attachment ↗alxo-ex99_1.htm · 8-K · 2026-06-30
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph. D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif., June 30, 2026 - ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology compan…
Read attachment ↗alxo-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and…
Read attachment ↗alxo-ex99_1.htm · 8-K · 2026-04-13
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies…
Read attachment ↗alxo-ex99_1.htm · 8-K · 2026-02-27
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by da…
Read attachment ↗